19 hours ago
Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients
SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced positive results from two Phase 2 clinical trials of PER-001, a novel therapeutic designed to address two leading causes of global blindness: glaucoma and diabetic retinopathy. Each of the six month, randomized, controlled trials evaluated PER-001, a first-in-class endothelin antagonist delivered in a slow-release, dissolvable implant that is injected into the back of the eye (intravitreal) every six months. Significant improvement in vision was demonstrated compared to control in each trial.
With a therapy that targets the underlying cause of both diseases, early results of PER-001 show promise for transforming the trajectory of human blindness and offer evidence of PER-001's ability to reverse the course of progressive vision loss. The goal of this approach is to improve retinal blood flow and prevent the death of retinal cells that occur in ocular diseases. Ph2b/3 trials are planned to begin in the second half of 2025.
'Our goal is to pioneer the first disease-modifying treatment for ocular diseases that share a common underlying pathology of ischemia—starting with glaucoma and diabetic retinopathy and rapidly expanding into dry age-related macular degeneration,' said Phil Lai, MD, chief medical officer of Perfuse Therapeutics. 'Our studies demonstrated that PER-001 has the potential to transform care for leading causes of blindness, delivering sustained benefits that not only prevent blindness but also improve vision.'
New Hope for Glaucoma Patients: Restoring Vision by Targeting the Root Cause
Glaucoma is the leading cause of global blindness worldwide. An estimated 4.2 million people in the U.S. have glaucoma, but only about half are aware of their condition. Currently there are no glaucoma therapies approved by the U.S. Food and Drug Administration; treatments primarily consist of pharmacological, laser or surgical solutions to reduce intraocular pressure (IOP), which is normal in around half of glaucoma patients. Unfortunately, even with reduction of IOP, many patients progress to blindness.
Key findings from the Phase 2a glaucoma trial showed that after single intravitreal administration of PER-001 released for six months, added to existing standard-of-care IOP-reducing therapies:
'Many people continue to have worsening glaucoma despite what is considered to be safe IOP. A holy grail in the treatment of glaucoma is the ability to reduce optic nerve damage by means other than lowering IOP,' said Joel Schuman, MD, professor and K.L. Roper Endowed Chair, Department of Ophthalmology at Wills Eye Hospital and president of Collaborative Community on Ophthalmic Innovation (CCOI). 'For the first time, Perfuse's Phase 2a glaucoma trial demonstrates neuroenhancement, improvement in the function of existing optic nerve tissue, in humans with glaucoma. Patients treated with PER-001 in this trial remarkably showed improvement in visual field performance, while those in the control group continued to deteriorate. The 7 dB scale of improvement in the Garway-Heath visual field sectors at a minimum of 5 testable points, is generally considered clinically significant and has been employed in the past by the U.S. Food and Drug Administration (FDA) as one criterion in considering approval of a new agent for glaucoma. In addition to enhancement of visual function, patients receiving PER-001 demonstrated improvements in ocular blood flow and optic nerve structure. Importantly, there is currently no FDA-approved drug for the treatment of glaucoma. The current study results are most encouraging, demonstrating the potential for a radically new, transformational treatment approach for this disease.'
Improving Vision and Ischemia in Diabetic Retinopathy
An estimated 9.6 million people in the U.S. are living with diabetic retinopathy, including more than 1.8 million with vision-threatening complications. Globally, diabetic retinopathy remains the leading cause of blindness among working age adults.
Current treatment typically revolves around stabilization or improvement of a structural outcome, the Diabetic Retinopathy Severity Scale (DRSS), with no long-term benefit in vision. In many cases, peripheral vision is destroyed by laser treatment with hopes of maintaining central vision. Unfortunately, many patients continue to experience vision loss, even with available therapies.
Key findings from the diabetic retinopathy Phase 2a trial showed a single intravitreal administration of PER-001 released for six months led to:
Details of this phase are published in " PER-001, A Novel, Long Acting Endothelin Antagonist IVT Implant for the Treatment of Retinal Ischemia in Glaucoma, Diabetic Retinopathy and Age Related Macular Degeneration,' which was presented at Clinical Trials at the Summit (CTS) meeting on June 21.
'The results from the Ph2a study of PER-001 represent a major advancement in the treatment of diabetic retinopathy. For the first time, we're seeing a therapy for diabetic retinopathy that shows improvement in visual function,' said Arshad Khanani, MD, Clinical Professor of Ophthalmology at University of Nevada and Director of Clinical Research at Sierra Eye Associates, who presented the results at the CTS meeting. 'These functional gains in peripheral vision, contrast sensitivity and visual acuity accompanied by structural improvements in retinal ischemia, leakage, and microaneurysm validate the PER-001 mechanism of action. By targeting the endothelin pathway, PER-001 introduces a novel, every 6 months therapy, that can address the underlying neurovascular disease and offer vision benefits with the potential to be disease modifying for diabetic retinopathy and other ischemic retinal conditions.'
A total of 60 patients were treated in both trials; 33 participants were enrolled in the glaucoma Ph1/2a and 27 participants in the diabetic retinopathy Ph2a study. The 24-week data demonstrated that PER-001 was safe and well-tolerated in both trials.
With these encouraging results, Perfuse Therapeutics plans to initiate pivotal trials across both indications with a larger population of patients over a longer period, starting in the second half of 2025.
About PER-001
PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma, diabetic retinopathy, age related macular degeneration and retinal vein occlusion. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. The PER-001 intravitreal implant is a bio-erodible implant administered into the vitreous cavity of the eye using a single-use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient dosing every six months.
About Perfuse Therapeutics
Perfuse Therapeutics is a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is developing a robust pipeline of novel assets against validated targets. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. For more information, visit and LinkedIn.
Investor Relations and Media Contact [email protected].
View original content to download multimedia:
SOURCE Perfuse Therapeutics
